Physician profile

Jay J Rubin

Neuromusculoskeletal Medicine & OMM · Ocala, FL

NPI 1649294448

$990.02

in general payments reported to CMS, 2019-2025

24 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Medtronic Vascular, INC. $198.97 2019
Sk Life Science, INC. $123.27 2020
Acadia Pharmaceuticals INC $103.03 2019-2020
Alexion Pharmaceuticals, INC. $76.68 2019-2020
Eisai INC. $72.29 2019
Lilly USA, LLC $66.81 2019-2020
Mdd US Operations, LLC $54.59 2019-2020
Acorda Therapeutics, INC $48.21 2019-2020
Grifols USA, LLC $37.58 2019
Novartis Pharmaceuticals Corporation $33.33 2019-2020
Jazz Pharmaceuticals INC. $31.18 2019-2020
Sunovion Pharmaceuticals INC. $26.66 2019
Alnylam Pharmaceuticals INC. $25.72 2020
Ge Healthcare $25.08 2019
Avanir Pharmaceuticals, INC. $19.88 2019
Show all 18 companies
CompanyGeneral paymentsYearsTop products
Ucb, INC. $17.34 2019
Si-Bone, INC. $15.28 2019
Nevro Corp. $14.12 2019

6 companies reported research payments only; those appear in the research section below.

Research and ownership

$19,394,281.02 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jay J Rubin

$990.02

in general payments reported 2019-2025

Years
2019-2024
Top company
Medtronic Vascular, INC.

https://glasscript.com/doctor/301802/jay-j-rubin

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.